Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Athira Pharma Inc shares valued at $1 were purchased by Mark James Litton on Sep 05 ’24. At $0.00 per share, Mark James Litton acquired 5,032 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Gengos Andrew sold 1,272 shares, netting a total of over 720 in proceeds. Following the sale of shares at $0.57 each, the insider now holds 97,532 shares.
Before that, Lenington Rachel had sold 2,525 shares from its account. In a trade valued at $1,429, the COO and CDO traded Athira Pharma Inc shares for $0.57 each. Upon closing the transaction, the insider’s holdings decreased to 2,525 shares, worth approximately $9182.8.
As published in a research note from Mizuho on September 19, 2024, Athira Pharma Inc [ATHA] has been rated down from an Outperform to a Neutral and the price target has been revised to $0.50 from $5. Analysts at Rodman & Renshaw downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early September. As of September 04, 2024, JMP Securities has decreased its “Mkt outperform” rating to a “Mkt perform” for ATHA. Earlier on September 04, 2024, BTIG Research downgraded its rating. Their new recommendation was “a Neutral” for ATHA stock which previously was a “a Buy”.
Analyzing ATHA Stock Performance
During the last five days, there has been a drop of approximately -5.64%. Over the course of the year, Athira Pharma Inc shares have dropped approximately -82.02%. Shares of the company reached a 52-week high of $4.2984 on 02/21/24 and a 52-week low of $0.4128 on 09/23/24. A 50-day SMA is recorded $2.3206, while a 200-day SMA reached $2.6205. Nevertheless, trading volume fell to 0.54 million shares from 1.85 million shares the previous day.
Support And Resistance Levels for Athira Pharma Inc (ATHA)
According to the 24-hour chart, there is a support level at 0.4213, which, if violated, would cause prices to drop to 0.4056. In the upper region, resistance lies at 0.4613. The next price resistance is at 0.4856. RSI (Relative Strength Index) is 17.02 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0447, which suggests the price will decrease in the coming days. Percent R is at 85.55%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
